Is CSL (ASX:CSL) now facing a more difficult FY24 than investors first thought?

After a decade of nothing but good news for investors in CSL (ASX:CSL), shares fell last week after the company…

Nova Eye Medical (ASX:EYE) has been on a strong run, up 50% in one month. Is there more upside?

Nova Eye Medical (ASX:EYE) has had a good month. The optometry company obtained FDA clearance for its newest generation canaloplasty device…

Why did biotech shares underperform in 2022 and will they rebound with a vengence in 2023?

In the past year, biotech shares have performed poorly. Why has this been the case and will things be better…

Which ASX health stocks might get FDA approval in 2023?

It is the dream of many ASX health stocks and their investors for their company’s device or drug to be…

Immutep (ASX: IMM) has massive potential!

Immutep (ASX: IMM) develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. It has several product candidates at…

Actinogen Medical (ASX: ACW): Good news on phase 2 trials can catapult this stock

Working on a new drug for Alzheimer’s disease Actinogen Medical (ASX: ACW) is a Sydney-based biotechnology company working on finding…

Can Telix Pharmaceuticals rise to become the next CSL by 2025?

Biotech company Telix Pharmaceuticals (ASX: TLX) completed the first commercial quarter of its prostate cancer imaging product Illuccix. This follows…

Dimerix (ASX:DXB): Good news on Phase 3 trials can catapult this stock

Stay up-to-date on ASX-listed stocks! Get a 14-day FREE TRIAL Dimerix has lots of irons in the fire Dimerix…

Pfizer delivers the goods on a COVID-19 vaccine

10 November 2020 One of the reasons investors can be optimistic about 2021 is the speed with which the first…

Life Sciences